Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer

Amy L. Jonson, Lisa M. Rogers, Sundaram Ramakrishnan, Levi S. Downs

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Objective: Selective silencing of HPV oncogenes using short interfering RNA (siRNA) blocks E6/E7 expression and restores normal p53 and Rb function. Our objective was to determine if siRNA targeting E6/E7 would inhibit the growth of established tumors in a mouse model of cervical cancer. Methods: In vitro studies were performed using unique siRNA sequences to confirm their ability to target and reduce E6/E7 mRNA and restore functioning p53. Next, siRNA targeting lamin was injected daily for three days into tumors established from HPV 16 positive CaSki human cervical cancer cells. Immunohistochemistry and branched DNA gene quantification were used to determine distribution and duration of activity of these siRNA. For our therapeutic studies tumors were directly injected with siRNA targeting E6/E7, non-targeting control siRNA, or saline. In preliminary experiments injections were daily or every three days for a total of three doses. A second therapeutic experiment utilized every three day dosing for 35 days. Tumor volume, growth curves and E7 mRNA levels were assessed. Results: The two most active siRNA sequences resulted in a 67% and 71% reduction in E6/E7 mRNA. Fluorescent lamin siRNA was visualized up to 120 h after the initial tumor injection and was evenly distributed throughout the tumors. IHC showed lamin expression to be inhibited by 68% and 75% when compared to controls at 54 and 120 h respectively. In our preliminary therapeutic intervention experiments there was no significant difference in tumor growth between the treatment groups when mice were treated with three daily injections (p = 0.41). However, when treated every third day for three injections final tumor volume was less in animals injected with siRNA sequences A (78% reduction; p < 0.0001) and G (60% reduction; p = 0.005) compared to saline injection. Tumors showed a corresponding decrease in E6/E7 mRNA. Extended treatment with siRNA completely or nearly eradicated tumors in 70% of the animals. Conclusion: Therapeutic siRNA targeting E6/E7 significantly inhibits tumor growth in this mouse model of cervical cancer. Further investigation is needed to determine optimal dosing and route of delivery.

Original languageEnglish (US)
Pages (from-to)356-364
Number of pages9
JournalGynecologic Oncology
Volume111
Issue number2
DOIs
StatePublished - Nov 1 2008
Externally publishedYes

Fingerprint

Gene Silencing
Uterine Cervical Neoplasms
Small Interfering RNA
Lamins
Neoplasms
Therapeutics
Injections
Messenger RNA
Growth
Tumor Burden
Human papillomavirus 16
Oncogenes
Immunohistochemistry

Keywords

  • Cervical cancer
  • E6
  • E7
  • HPV
  • siRNA

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer. / Jonson, Amy L.; Rogers, Lisa M.; Ramakrishnan, Sundaram; Downs, Levi S.

In: Gynecologic Oncology, Vol. 111, No. 2, 01.11.2008, p. 356-364.

Research output: Contribution to journalArticle

@article{2c48b3f5d79e44e197930664d255a673,
title = "Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer",
abstract = "Objective: Selective silencing of HPV oncogenes using short interfering RNA (siRNA) blocks E6/E7 expression and restores normal p53 and Rb function. Our objective was to determine if siRNA targeting E6/E7 would inhibit the growth of established tumors in a mouse model of cervical cancer. Methods: In vitro studies were performed using unique siRNA sequences to confirm their ability to target and reduce E6/E7 mRNA and restore functioning p53. Next, siRNA targeting lamin was injected daily for three days into tumors established from HPV 16 positive CaSki human cervical cancer cells. Immunohistochemistry and branched DNA gene quantification were used to determine distribution and duration of activity of these siRNA. For our therapeutic studies tumors were directly injected with siRNA targeting E6/E7, non-targeting control siRNA, or saline. In preliminary experiments injections were daily or every three days for a total of three doses. A second therapeutic experiment utilized every three day dosing for 35 days. Tumor volume, growth curves and E7 mRNA levels were assessed. Results: The two most active siRNA sequences resulted in a 67{\%} and 71{\%} reduction in E6/E7 mRNA. Fluorescent lamin siRNA was visualized up to 120 h after the initial tumor injection and was evenly distributed throughout the tumors. IHC showed lamin expression to be inhibited by 68{\%} and 75{\%} when compared to controls at 54 and 120 h respectively. In our preliminary therapeutic intervention experiments there was no significant difference in tumor growth between the treatment groups when mice were treated with three daily injections (p = 0.41). However, when treated every third day for three injections final tumor volume was less in animals injected with siRNA sequences A (78{\%} reduction; p < 0.0001) and G (60{\%} reduction; p = 0.005) compared to saline injection. Tumors showed a corresponding decrease in E6/E7 mRNA. Extended treatment with siRNA completely or nearly eradicated tumors in 70{\%} of the animals. Conclusion: Therapeutic siRNA targeting E6/E7 significantly inhibits tumor growth in this mouse model of cervical cancer. Further investigation is needed to determine optimal dosing and route of delivery.",
keywords = "Cervical cancer, E6, E7, HPV, siRNA",
author = "Jonson, {Amy L.} and Rogers, {Lisa M.} and Sundaram Ramakrishnan and Downs, {Levi S.}",
year = "2008",
month = "11",
day = "1",
doi = "10.1016/j.ygyno.2008.06.033",
language = "English (US)",
volume = "111",
pages = "356--364",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer

AU - Jonson, Amy L.

AU - Rogers, Lisa M.

AU - Ramakrishnan, Sundaram

AU - Downs, Levi S.

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Objective: Selective silencing of HPV oncogenes using short interfering RNA (siRNA) blocks E6/E7 expression and restores normal p53 and Rb function. Our objective was to determine if siRNA targeting E6/E7 would inhibit the growth of established tumors in a mouse model of cervical cancer. Methods: In vitro studies were performed using unique siRNA sequences to confirm their ability to target and reduce E6/E7 mRNA and restore functioning p53. Next, siRNA targeting lamin was injected daily for three days into tumors established from HPV 16 positive CaSki human cervical cancer cells. Immunohistochemistry and branched DNA gene quantification were used to determine distribution and duration of activity of these siRNA. For our therapeutic studies tumors were directly injected with siRNA targeting E6/E7, non-targeting control siRNA, or saline. In preliminary experiments injections were daily or every three days for a total of three doses. A second therapeutic experiment utilized every three day dosing for 35 days. Tumor volume, growth curves and E7 mRNA levels were assessed. Results: The two most active siRNA sequences resulted in a 67% and 71% reduction in E6/E7 mRNA. Fluorescent lamin siRNA was visualized up to 120 h after the initial tumor injection and was evenly distributed throughout the tumors. IHC showed lamin expression to be inhibited by 68% and 75% when compared to controls at 54 and 120 h respectively. In our preliminary therapeutic intervention experiments there was no significant difference in tumor growth between the treatment groups when mice were treated with three daily injections (p = 0.41). However, when treated every third day for three injections final tumor volume was less in animals injected with siRNA sequences A (78% reduction; p < 0.0001) and G (60% reduction; p = 0.005) compared to saline injection. Tumors showed a corresponding decrease in E6/E7 mRNA. Extended treatment with siRNA completely or nearly eradicated tumors in 70% of the animals. Conclusion: Therapeutic siRNA targeting E6/E7 significantly inhibits tumor growth in this mouse model of cervical cancer. Further investigation is needed to determine optimal dosing and route of delivery.

AB - Objective: Selective silencing of HPV oncogenes using short interfering RNA (siRNA) blocks E6/E7 expression and restores normal p53 and Rb function. Our objective was to determine if siRNA targeting E6/E7 would inhibit the growth of established tumors in a mouse model of cervical cancer. Methods: In vitro studies were performed using unique siRNA sequences to confirm their ability to target and reduce E6/E7 mRNA and restore functioning p53. Next, siRNA targeting lamin was injected daily for three days into tumors established from HPV 16 positive CaSki human cervical cancer cells. Immunohistochemistry and branched DNA gene quantification were used to determine distribution and duration of activity of these siRNA. For our therapeutic studies tumors were directly injected with siRNA targeting E6/E7, non-targeting control siRNA, or saline. In preliminary experiments injections were daily or every three days for a total of three doses. A second therapeutic experiment utilized every three day dosing for 35 days. Tumor volume, growth curves and E7 mRNA levels were assessed. Results: The two most active siRNA sequences resulted in a 67% and 71% reduction in E6/E7 mRNA. Fluorescent lamin siRNA was visualized up to 120 h after the initial tumor injection and was evenly distributed throughout the tumors. IHC showed lamin expression to be inhibited by 68% and 75% when compared to controls at 54 and 120 h respectively. In our preliminary therapeutic intervention experiments there was no significant difference in tumor growth between the treatment groups when mice were treated with three daily injections (p = 0.41). However, when treated every third day for three injections final tumor volume was less in animals injected with siRNA sequences A (78% reduction; p < 0.0001) and G (60% reduction; p = 0.005) compared to saline injection. Tumors showed a corresponding decrease in E6/E7 mRNA. Extended treatment with siRNA completely or nearly eradicated tumors in 70% of the animals. Conclusion: Therapeutic siRNA targeting E6/E7 significantly inhibits tumor growth in this mouse model of cervical cancer. Further investigation is needed to determine optimal dosing and route of delivery.

KW - Cervical cancer

KW - E6

KW - E7

KW - HPV

KW - siRNA

UR - http://www.scopus.com/inward/record.url?scp=55649097304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55649097304&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2008.06.033

DO - 10.1016/j.ygyno.2008.06.033

M3 - Article

C2 - 18755502

AN - SCOPUS:55649097304

VL - 111

SP - 356

EP - 364

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -